CALA HEALTH, INC.

Cala Health and University of California, San Francisco Announce Partnership to Develop Next-Generation, Smart Neuromodulation Therapies

Retrieved on: 
Thursday, June 17, 2021
Cardiology, Biotechnology, Pharmaceutical, Health, Mental health, Medical devices, Technology, Other Technology, Branches of biology, Neuroscience, Neurotechnology, Sunset District, San Francisco, University of California, San Francisco, Neuromodulation, CALA, Medicine, Cala Health, Inc., University of California, San Francisco, CALA HEALTH, INC., UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today announced a partnership with University of California, San Francisco (UCSF) to develop non-invasive, individualized, peripheral nerve stimulation therapies that leverage Cala Healths neuromodulation and data science platform technology.

Key Points: 
  • Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today announced a partnership with University of California, San Francisco (UCSF) to develop non-invasive, individualized, peripheral nerve stimulation therapies that leverage Cala Healths neuromodulation and data science platform technology.
  • Cala Health is merging breakthroughs in neuroscience and technology to transform the standard of care for chronic disease.
  • Cala Health Inc., an award-winning bioelectronic medicine company, headquartered in the San Francisco Bay area, is transforming the standard of care for chronic disease.
  • Cala Health has new therapies under development in neurology, cardiology, and mental health and is backed by leading investors in both healthcare and technology.

Cala Health Reports New Data Demonstrating Increasing Prevalence of Essential Tremor (ET) and High Rates of Depression and Anxiety in Patients With ET

Retrieved on: 
Monday, November 16, 2020
Other Health, Other Science, Other Professional Services, Pharmaceutical, Research, Insurance, Mental health, Medical devices, Hospitals, Professional services, Science, Nursing, Managed care, Medical Supplies, General Health, Biotechnology, Surgery, Health, Essential tremor, Tremor, Branches of biology, Neuroscience, Medical specialties, Essential Tremor (ET), Cala TrioTM, Cala Health, Inc., The International Essential Tremor Foundation

These findings demonstrate that many patients with ET remain untreated, and the findings on depression and anxiety are consistent with prior reports in the literature as common comorbidities for patients with ET.

Key Points: 
  • These findings demonstrate that many patients with ET remain untreated, and the findings on depression and anxiety are consistent with prior reports in the literature as common comorbidities for patients with ET.
  • Cala TrioTM is the first non-invasive targeted therapy that reduces hand tremors for adults living with Essential Tremor (ET).
  • Therapy is conveniently delivered to the patient's home, and Cala Health educates patients based on how they learnphone, video, user portal.
  • Founded in 1988, the International Essential Tremor Foundation (IETF) is the leading organization in the world dedicated to people affected by essential tremor (ET).

Cala Health Receives FDA Breakthrough Device Designation for Cala Trio™ Therapy to Treat Action Tremors in Parkinson's Disease

Retrieved on: 
Thursday, October 22, 2020
Venture capital, Biotechnology, Pharmaceutical, Health, FDA, Medical devices, Professional services, Clinical trials, Branches of biology, Clinical medicine, Nervous system, Essential tremor, Tremor, Parkinson's disease, CALA, Transcutaneous electrical nerve stimulation, Venture capital, Biotechnology, Pharmaceutical, Health, FDA, Medical devices, Professional services, Clinical trials, Branches of biology, Clinical medicine, Nervous system, Essential tremor, Tremor, Parkinson's disease, CALA, Transcutaneous electrical nerve stimulation, Action Tremor, Essential Tremor (ET), Cala Trio™, Cala Health, Inc.

Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Cala Trio for the treatment of action tremors in the hands of adults with Parkinson's disease.

Key Points: 
  • Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Cala Trio for the treatment of action tremors in the hands of adults with Parkinson's disease.
  • Cala Health sought Breakthrough Device Designation for Cala Trio because many patients with Parkinson's disease experience the same action tremor as patients with essential tremor.
  • The Company expects to initiate the next clinical trials of Cala Trio virtually in patients with Parkinson's disease in 2020.
  • Cala Trio is the first non-invasive targeted therapy that reduces hand tremors for adults living with Essential Tremor (ET).

First Real-World Evidence Demonstrates Cala Trio's Effectiveness in Essential Tremor with Individually Calibrated, Non-Invasive Stimulation

Retrieved on: 
Monday, September 14, 2020
Other Health, Software, MEN, Hardware, Consumer electronics, Consumer, Medical devices, Technology, Clinical trials, Women, Seniors, Health, Organ systems, Nervous system, Essential tremor, Tremor, CALA, Neurological disorders, Neurophysiology, Neuromodulation, Essential Tremor (ET), Cala TrioTM, Cala Health, Inc.

Forty-four patients used Cala Trio for symptomatic tremor relief in hand tremors during three months of non-supervised home use.

Key Points: 
  • Forty-four patients used Cala Trio for symptomatic tremor relief in hand tremors during three months of non-supervised home use.
  • Cala TrioTM is the first non-invasive targeted therapy that reduces hand tremors for adults living with Essential Tremor (ET).
  • Cala Health's lead product, Cala TrioTM, is the only individualized, non-invasive, wrist-worn prescription therapy for essential tremor.
  • Cala Health is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Cala Health Announces Continued Growth and Momentum with Clinical, Product Development, and Management Milestones to Support Cala Trio Therapy for the Treatment of Essential Tremor

Retrieved on: 
Monday, August 17, 2020
Biotechnology, FDA, Health, Clinical trials, Managed care, Organ systems, Nervous system, Essential tremor, Tremor, Neurological disorders, Neurophysiology, Neuromodulation, Essential Tremor (ET), Cala Trio, Cala Health, Inc.

In Quality of Life in Essential Tremor (QUEST) surveys conducted after three months of use, patients indicated their quality of life improved (p=0.0019).

Key Points: 
  • In Quality of Life in Essential Tremor (QUEST) surveys conducted after three months of use, patients indicated their quality of life improved (p=0.0019).
  • Cala Trio is the first non-invasive targeted therapy that reduces hand tremors for adults living with Essential Tremor (ET).
  • Cala Health's lead product, Cala Trio, is the only non-invasive, wrist-worn prescription therapy for essential tremor.
  • Cala Health is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™

Retrieved on: 
Thursday, January 9, 2020
Branches of biology, Organ systems, Neuroscience, Neurophysiology, Neurotechnology, Electrotherapy, Neurological disorders, Neuromodulation, Neuropsychology, Tremor, Functional electrical stimulation, Essential tremor

The on-demand electrical stimulation is based on the individual tremor patterns, and takes personalized therapy to the next level.

Key Points: 
  • The on-demand electrical stimulation is based on the individual tremor patterns, and takes personalized therapy to the next level.
  • ET is the most prevalent tremor disorder and one of the most common neurological disorders, affecting an estimated seven million people in the United States.
  • "Cala Health has emerged a pioneer in treating ET for the upper limbs through peripheral nerve stimulation.
  • "Cala Health is also actively licensing technologies from academic medical centers to incorporate them in its neuromodulation platform.

Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™

Retrieved on: 
Thursday, January 9, 2020
Branches of biology, Organ systems, Neuroscience, Neurophysiology, Neurotechnology, Electrotherapy, Neurological disorders, Neuromodulation, Neuropsychology, Tremor, Functional electrical stimulation, Essential tremor

The on-demand electrical stimulation is based on the individual tremor patterns, and takes personalized therapy to the next level.

Key Points: 
  • The on-demand electrical stimulation is based on the individual tremor patterns, and takes personalized therapy to the next level.
  • ET is the most prevalent tremor disorder and one of the most common neurological disorders, affecting an estimated seven million people in the United States.
  • "Cala Health has emerged a pioneer in treating ET for the upper limbs through peripheral nerve stimulation.
  • "Cala Health is also actively licensing technologies from academic medical centers to incorporate them in its neuromodulation platform.

Cala Health Names Veteran Leader Renee Ryan as Chief Executive Officer

Retrieved on: 
Wednesday, September 4, 2019
Research, Medical devices, Infectious diseases, Biotechnology, Pharmaceutical, Health, Science, Heal.com

Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today announced that it has named Renee Ryan as Chief Executive Officer (CEO).

Key Points: 
  • Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today announced that it has named Renee Ryan as Chief Executive Officer (CEO).
  • Founder and current CEO Kate Rosenbluth will continue to lead in the role of Founder and Chief Scientific Officer and serve on the Board of Directors.
  • Ryan has been a member of Cala Healths Board of Directors since the companys inception in 2014.
  • Im very pleased to partner with Renee to fuel the healthy growth and expansion of Cala Health, Rosenbluth said.